紫杉醇与帕唑帕尼治疗卵巢癌的回复 - Suppr

Suppr

超能文献

Paclitaxel and Pazopanib in Ovarian Cancer-Reply.

作者信息

Richardson Debra L, Coleman Robert L, Sill Michael W

机构信息

Section of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma, Oklahoma City.

University of Texas, MD Anderson Cancer Center, Houston.

出版信息

JAMA Oncol. 2018 Sep 1;4(9):1299. doi: 10.1001/jamaoncol.2018.1712.

DOI:10.1001/jamaoncol.2018.1712

PMID:29978183

Abstract

摘要

相似文献

Paclitaxel and Pazopanib in Ovarian Cancer-Reply.紫杉醇与帕唑帕尼治疗卵巢癌的回复

JAMA Oncol. 2018 Sep 1;4(9):1299. doi: 10.1001/jamaoncol.2018.1712.

Paclitaxel and Pazopanib in Ovarian Cancer.紫杉醇与帕唑帕尼治疗卵巢癌

JAMA Oncol. 2018 Sep 1;4(9):1298-1299. doi: 10.1001/jamaoncol.2018.1695.

Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.紫杉醇联合或不联合帕唑帕尼治疗持续性或复发性卵巢癌的随机临床试验。

JAMA Oncol. 2018 Feb 1;4(2):196-202. doi: 10.1001/jamaoncol.2017.4218.

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.帕唑帕尼联合每周紫杉醇与单独每周紫杉醇治疗铂耐药或铂难治性晚期卵巢癌（MITO 11）：一项随机、开放标签、2 期试验。

Lancet Oncol. 2015 May;16(5):561-8. doi: 10.1016/S1470-2045(15)70115-4. Epub 2015 Apr 14.

Targeting the microenvironment in ovarian cancer.针对卵巢癌的微环境

Lancet Oncol. 2015 May;16(5):485-6. doi: 10.1016/S1470-2045(15)70157-9. Epub 2015 Apr 14.

Paclitaxel and Alisertib in Recurrent Ovarian Cancer-In Reply.紫杉醇与阿利西替尼用于复发性卵巢癌——回应

JAMA Oncol. 2019 Jun 1;5(6):910-911. doi: 10.1001/jamaoncol.2019.0562.

Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.基于帕唑帕尼的口服小剂量持续化疗治疗铂耐药/难治性上皮性卵巢癌：一项II期、开放标签、随机对照试验。

Gynecol Oncol. 2021 Aug;162(2):382-388. doi: 10.1016/j.ygyno.2021.05.025. Epub 2021 Jun 2.

Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer.帕唑帕尼与口服环磷酰胺用于铂耐药或难治性上皮性卵巢癌女性患者的治疗

JCO Glob Oncol. 2020 Mar;6:542-547. doi: 10.1200/JGO.19.00331.

Symptomatic Sinus Bradycardia in a Patient with Solitary Fibrous Tumor/Hemangiopericytoma Treated with Pazopanib.帕唑帕尼治疗孤立性纤维肿瘤/血管外皮细胞瘤患者的症状性窦性心动过缓。

Intern Med. 2021 Sep 15;60(18):2973-2977. doi: 10.2169/internalmedicine.5347-20. Epub 2021 Apr 5.

The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.PACOVAR 试验：帕唑帕尼（GW786034）联合环磷酰胺治疗铂类耐药复发性、预处理卵巢癌的 I/II 期研究。

BMC Cancer. 2011 Oct 20;11:453. doi: 10.1186/1471-2407-11-453.

引用本文的文献

Tanshinone IIA suppresses ovarian cancer growth through inhibiting malignant properties and angiogenesis.丹参酮IIA通过抑制恶性特性和血管生成来抑制卵巢癌生长。

Ann Transl Med. 2020 Oct;8(20):1295. doi: 10.21037/atm-20-5741.

[F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer.[F]氟西拉肽正电子发射断层扫描作为铂耐药/难治性卵巢癌中帕唑帕尼和紫杉醇联合治疗反应的生物标志物。

Eur J Nucl Med Mol Imaging. 2020 May;47(5):1239-1251. doi: 10.1007/s00259-019-04532-z. Epub 2019 Nov 21.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Paclitaxel and Pazopanib in Ovarian Cancer-Reply.

作者信息

Richardson Debra L, Coleman Robert L, Sill Michael W

机构信息

Section of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma, Oklahoma City.

University of Texas, MD Anderson Cancer Center, Houston.

出版信息

JAMA Oncol. 2018 Sep 1;4(9):1299. doi: 10.1001/jamaoncol.2018.1712.

DOI:10.1001/jamaoncol.2018.1712

PMID:29978183

Abstract

摘要